Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 11/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.54 |
| ▸ | GSK3A | P49840 | 11/20 | 0.54 |
| ▸ | GSK3B | P49841 | 11/20 | 0.54 |
| ▸ | CDK1 | P06493 | 9/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 8/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.54 |
| ▸ | AURKC | Q9UQB9 | 5/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | CDK4 | P11802 | 2/20 | 0.54 |
| ▸ | CCND1 | P24385 | 2/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | SGK1 | O00141 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064946 | 0.75 | CDK5 (0.60) | CDK5CDK5R1GSK3AGSK3BCDK1 | |
| SCHEMBL24487476 | 0.74 | AHR (0.52) | CDK1CCNB2CCNB1CCNB3CDK4 | |
| SCHEMBL22457398 | 0.73 | AHR (0.56) | GSK3BCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL1202543 | 0.73 | IMPDH2 (0.63) | CDK1CCNB2CCNB1CCNB3CDK4 | |
| SCHEMBL22443303 | 0.72 | PDE10A (0.55) | CDK1CCNB2CCNB1CCNB3CDK4 | |
| Indirubin-3-Monoxime SCHEMBL29354191 | 0.70 | CDK5R1 (1.00) | CDK5CDK5R1GSK3AGSK3BCDK1 | |
| SCHEMBL18117823 | 0.70 | GSK3B (0.50) | CDK5CDK5R1GSK3AGSK3BCDK1 | |
| SCHEMBL11174102 | 0.69 | AHR (0.55) | CDK5CDK5R1GSK3AGSK3BCDK1 | |
| SCHEMBL29924508 | 0.69 | GSK3B (0.72) | CDK5CDK5R1GSK3AGSK3BCDK1 | |
| SCHEMBL7363256 | 0.69 | HPGD (0.48) | CDK1CCNB2CCNB1CCNB3CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | CDK5 4473/4885CDK5R1 4302/4885GSK3A 3016/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | CDK5 4473/4885CDK5R1 4302/4885GSK3A 3016/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | CDK5 4473/4885CDK5R1 4302/4885GSK3A 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.